Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy | Zendy

Arpan Patel | Zendy; James Sul | Zendy; Marc L. Gordon | Zendy; Jared Steinklein | Zendy; Shayna Y. Sanguinetti | Zendy; Bidyut K. Pramanik | Zendy; Dushyant P. Purohit | Zendy; Vahram Haroutunian | Zendy; Alex Williamson | Zendy; Igor J. Koralnik | Zendy; Asaff Harel | Zendy

Open Access

Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy

Author(s) -

Arpan Patel,

James Sul,

Marc L. Gordon,

Jared Steinklein,

Shayna Y. Sanguinetti,

Bidyut K. Pramanik,

Dushyant P. Purohit,

Vahram Haroutunian,

Alex Williamson,

Igor J. Koralnik,

Asaff Harel

Publication year - 2021

Publication title -

jama neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.298

H-Index - 231

eISSN - 2168-6157

pISSN - 2168-6149

DOI - 10.1001/jamaneurol.2021.0627

Subject(s) - medicine , ocrelizumab , progressive multifocal leukoencephalopathy , jc virus , multiple sclerosis , surgery , immunology , rituximab , lymphoma

Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection caused by the JC virus that has no proven effective treatment. Although rare cases of PML have occurred with other anti-CD20 therapies, there had been no prior cases associated with ocrelizumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog